HCM
HUTCHMED (China) Limited
There isn't enough reported data to score HCM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HCM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
HCM's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.1x | $2.63 | -82% |
| Current | 5.7x | $14.85 | — |
| Fair | 5.8x | $3.00 | -80% |
| Expensive | 67x | $34.83 | +135% |
Historical ranges are pointers, not guarantees.
HCM's PE is 5.7x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over HCM in the historical PE scenario, which offers more potential upside but is not a forecast.
HCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect HCM's losses to grow, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HCM on the outlook, with more favorable earnings expectations.
HCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.52 | +1200% |
| Q2 2025 | $0.53 | +$0.57 |
| Q4 2024 | $0.04 | -67% |
| Q2 2024 | -$0.04 | +$0.01 |
| Q4 2023 | $0.12 | +$0.55 |
| Q2 2023 | -$0.05 | +$0.25 |
| Q4 2022 | -$0.43 | -$0.18 |
| Q2 2022 | -$0.30 | -$0.05 |
HCM has the edge over LLY in the latest year-over-year earnings comparison.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
HCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $270.8M | -17% |
| Q2 2025 | $277.7M | -9.2% |
| Q4 2024 | $324.5M | +6.4% |
| Q2 2024 | $305.7M | -43% |
| Q4 2023 | $305.1M | +36% |
| Q2 2023 | $532.9M | +164% |
| Q4 2022 | $224.4M | +13% |
| Q2 2022 | $202M | +28% |
HCM's revenue has slid since its 2023 peak: $271M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +17 points |
| Q2 2025 | -1.3% | -22 points |
| Q4 2024 | -5% | +89 points |
| Q2 2024 | -9% | +88 points |
| Q4 2023 | -31% | +62 points |
| Q2 2023 | 21% | +112 points |
| Q4 2022 | -94% | +3.8 points |
| Q2 2022 | -97% | -24 points |
HCM's operating margin was −13% last quarter, up 17 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HCM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
HCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.4M | -90% |
| Q2 2025 | -$82.2M | -$32.2M |
| Q4 2024 | $32.5M | +$47.9M |
| Q2 2024 | -$49.9M | -125% |
| Q4 2023 | -$15.4M | +$184.3M |
| Q2 2023 | $202M | +$307.7M |
| Q4 2022 | -$199.7M | -$59.3M |
| Q2 2022 | -$105.6M | -$25.4M |
HCM has burned cash in most quarters: −$96M over the past year, against −$119M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
HCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +327K shares |
| 1 year | +0.4% | +3.7M shares |
| 3 years | +31% | +207M shares |
| 5 years | +46% | +273M shares |
HCM has 873M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $36.1M |
| Q4 2023 | — |
| Q2 2023 | $9.1M |
| Q4 2022 | — |
| Q2 2022 | $48.1M |
| Q4 2021 | $551,000 |
| Q2 2021 | $26.8M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -6.5x | Net Cash |
HCM has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 79.2 | Neutral |
HCM's weekly RSI is 59 (neutral) and its Stochastic is 79 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HCM PE vs Healthcare Sector
| Metric | HCM | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 46 | 29 | 17 pts above |
HCM has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.2 | 4.4% above |
| 20 week MA | $13.0 | 14% above |
| 50 week MA | $13.4 | 11% above |
| 100 week MA | $14.3 | 4% above |
| 200 week MA | $15.4 | 3.8% below |
HCM has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 3.8% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HCM on trend strength, trading above more of its moving averages.
HCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $29.5 | +16% |
| 2021 | $29.5 | $35.3 | +20% |
| 2022 | $35.3 | $14.0 | -60% |
| 2023 | $14.0 | $18.1 | +29% |
| 2024 | $18.1 | $14.3 | -21% |
| 2025 | $14.3 | $13.8 | -3.5% |
| 2026 YTD | $13.8 | $14.9 | +7.8% |
HCM has finished lower in three of the last six years. It's up 7.8% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HCM on returns for 2026, with the stronger performance.